Finding 1220712 (2025-001)

Material Weakness Repeat Finding
Requirement
I
Questioned Costs
-
Year
2025
Accepted
2026-06-29
Audit: 405476

Finding Text

No text available

Categories

No categories assigned yet.

Other Findings in this Audit

  • 1220649 2025-001
    Material Weakness Repeat
  • 1220650 2025-001
    Material Weakness Repeat
  • 1220651 2025-001
    Material Weakness Repeat
  • 1220652 2025-001
    Material Weakness Repeat
  • 1220653 2025-001
    Material Weakness Repeat
  • 1220654 2025-001
    Material Weakness Repeat
  • 1220655 2025-001
    Material Weakness Repeat
  • 1220656 2025-001
    Material Weakness Repeat
  • 1220657 2025-001
    Material Weakness Repeat
  • 1220658 2025-001
    Material Weakness Repeat
  • 1220659 2025-001
    Material Weakness Repeat
  • 1220660 2025-001
    Material Weakness Repeat
  • 1220661 2025-001
    Material Weakness Repeat
  • 1220662 2025-001
    Material Weakness Repeat
  • 1220663 2025-001
    Material Weakness Repeat
  • 1220664 2025-001
    Material Weakness Repeat
  • 1220665 2025-001
    Material Weakness Repeat
  • 1220666 2025-001
    Material Weakness Repeat
  • 1220667 2025-001
    Material Weakness Repeat
  • 1220668 2025-001
    Material Weakness Repeat
  • 1220669 2025-001
    Material Weakness Repeat
  • 1220670 2025-001
    Material Weakness Repeat
  • 1220671 2025-001
    Material Weakness Repeat
  • 1220672 2025-001
    Material Weakness Repeat
  • 1220673 2025-001
    Material Weakness Repeat
  • 1220674 2025-001
    Material Weakness Repeat
  • 1220675 2025-001
    Material Weakness Repeat
  • 1220676 2025-001
    Material Weakness Repeat
  • 1220677 2025-001
    Material Weakness Repeat
  • 1220678 2025-001
    Material Weakness Repeat
  • 1220679 2025-001
    Material Weakness Repeat
  • 1220680 2025-001
    Material Weakness Repeat
  • 1220681 2025-001
    Material Weakness Repeat
  • 1220682 2025-001
    Material Weakness Repeat
  • 1220683 2025-001
    Material Weakness Repeat
  • 1220684 2025-001
    Material Weakness Repeat
  • 1220685 2025-001
    Material Weakness Repeat
  • 1220686 2025-001
    Material Weakness Repeat
  • 1220687 2025-001
    Material Weakness Repeat
  • 1220688 2025-001
    Material Weakness Repeat
  • 1220689 2025-001
    Material Weakness Repeat
  • 1220690 2025-001
    Material Weakness Repeat
  • 1220691 2025-001
    Material Weakness Repeat
  • 1220692 2025-001
    Material Weakness Repeat
  • 1220693 2025-001
    Material Weakness Repeat
  • 1220694 2025-001
    Material Weakness Repeat
  • 1220695 2025-001
    Material Weakness Repeat
  • 1220696 2025-001
    Material Weakness Repeat
  • 1220697 2025-001
    Material Weakness Repeat
  • 1220698 2025-001
    Material Weakness Repeat
  • 1220699 2025-001
    Material Weakness Repeat
  • 1220700 2025-001
    Material Weakness Repeat
  • 1220701 2025-001
    Material Weakness Repeat
  • 1220702 2025-001
    Material Weakness Repeat
  • 1220703 2025-001
    Material Weakness Repeat
  • 1220704 2025-001
    Material Weakness Repeat
  • 1220705 2025-001
    Material Weakness Repeat
  • 1220706 2025-001
    Material Weakness Repeat
  • 1220707 2025-001
    Material Weakness Repeat
  • 1220708 2025-001
    Material Weakness Repeat
  • 1220709 2025-001
    Material Weakness Repeat
  • 1220710 2025-001
    Material Weakness Repeat
  • 1220711 2025-001
    Material Weakness Repeat
  • 1220713 2025-001
    Material Weakness Repeat
  • 1220714 2025-001
    Material Weakness Repeat
  • 1220715 2025-001
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.RD Correlate of Protection (CoP) Studies to Support Development of the cAd3-EBO-S (Sudan virus) Candidate Vaccine $4.96M
12.351 SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION $2.46M
93.RD BARDA RTOR BIO-AMT-2301: IDIQ Contact Management Support Activities $2.30M
93.352 CONSTRUCTION SUPPORT $2.22M
11.307 ECONOMIC ADJUSTMENT ASSISTANCE $2.03M
12.910 RESEARCH AND TECHNOLOGY DEVELOPMENT $519,438
93.RD Efficacy studies in SUDV (Gulu variant) challenged Rhesus macaque non-human primates (NHP) $482,352
93.859 BIOMEDICAL RESEARCH AND RESEARCH TRAINING $374,920
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $321,279
93.RD Efficacy Testing of a Marburg Virus Monoclonal Antibody Medical Countermeasure $314,452
93.279 DRUG USE AND ADDICTION RESEARCH PROGRAMS $259,382
93.360 BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT $115,262
93.393 CANCER CAUSE AND PREVENTION RESEARCH $97,197
93.853 EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS $93,661
93.838 LUNG DISEASES RESEARCH $79,814
93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH $54,568
93.837 CARDIOVASCULAR DISEASES RESEARCH $42,937
93.242 MENTAL HEALTH RESEARCH GRANTS $33,452
93.RD Strong Heart Study Cardiovascular Center $32,852
93.396 CANCER BIOLOGY RESEARCH $30,342
93.113 ENVIRONMENTAL HEALTH $20,784
12.RD Test Support to the Battelle Accelerated Therapeutics for Combating Acute Viral Epidemics (BAT-CAVE) Program $19,603
93.838 COVID-19: Lung Diseases Research $14,749
93.350 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES $12,402
93.847 DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH $7,096
93.262 OCCUPATIONAL SAFETY AND HEALTH PROGRAM $6,234
93.866 AGING RESEARCH $5,519
93.143 NIEHS SUPERFUND HAZARDOUS SUBSTANCES_BASIC RESEARCH AND EDUCATION $3,831
93.351 RESEARCH INFRASTRUCTURE PROGRAMS $929
93.RD Sample Prep and Irradiation $-3
93.855 COVID-19 Allergy and Infectious Diseases Research $-62,857